迈瑞展区内人头攒动，启元大模型、瑞影、瑞检等系列产品正进行现场演示，工作人员讲解产品特性， 吸引了众多观众咨询交流；西门子医疗展区内，几台磁共振成像设备静静陈列，专业讲解员围绕设备的 临床应用场景、影像清晰度提升等核心优势展开介绍，让观众近距离感受高端医疗装备的科技魅力。 一批AI药械、手术机器人领域的产品引人关注。精锋医疗展示了其自主研发的多孔腔镜手术机器人、 单孔腔镜手术机器人、支气管镜手术机器人等丰富完整的产品组合，并为观众演示精细的手术画面。粒 影科技发布的AI+药械研发公共服务平台，深度融合"AI蛋白质结构预测与设计""AI底盘细胞改造"等多 项自研核心技术，可将传统需数年的研发周期缩短至数月。 药械产值1576亿元 12月18日，2025深圳国际高性能医疗器械展暨创新医药展在深圳会展中心举行。此次展会设置了医学影 像及放疗、医学检验、应急救治及康复、人工智能及机器人、创新医药、供应链等"8+1+1"十大展区， 吸引了300余家全球医药与医疗器械领域的领军企业和机构参展，展示千余件创新产品，涵盖高端医疗 器械、创新药、生物制造、AI+药械、消费医疗、核心零部件等深圳乃至国内药械领域的最新成果，为 医 ...

Core Viewpoint - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray) announced plans to issue H-shares and list on the Hong Kong Stock Exchange to support its internationalization strategy and enhance capital strength [1] Group 1: Internationalization Strategy - The funds raised will be used to advance Mindray's international strategy, global business layout, increase R&D investment, and supplement operational funds, aligning with its three strategic directions: digitalization, streamlining, and internationalization [1] - Mindray is the only domestic medical device company in the global top 30, with a net asset of 39 billion yuan as of mid-2023 and a total dividend payout of 3.3 billion yuan this year, maintaining a dividend ratio of 65.1% [1][2] Group 2: Business Operations and Market Position - Mindray has established three main business segments: in vitro diagnostics, life information and support, and medical imaging, with a comprehensive product line in the industry [2] - The company has expanded its global presence with production bases in 14 countries, 12 R&D centers, and 64 overseas subsidiaries, employing over 3,000 local staff [2] - Mindray's overseas revenue has consistently grown for seven years, with international business accounting for 50% of total revenue in the first half of this year, indicating a deepening global strategy [2] Group 3: R&D and Innovation - R&D is considered the "lifeline" of Mindray, with R&D investment reaching 1.777 billion yuan in the first half of 2025, representing 10.61% of revenue, and a total of 20.646 billion yuan since its A-share listing in 2018 [3] - Mindray has integrated "equipment + IT + AI" and completed a digital medical ecosystem by 2025, enhancing its product offerings and transitioning to comprehensive digital solutions [3] - The successful listing in Hong Kong is expected to provide momentum for strategic collaboration, broaden financing channels, and enhance international brand recognition [3]